Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

Luchman HA, Chesnelong C, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Aug;15(8):979-80. doi: 10.1093/neuonc/not064. Epub 2013 Jun 11. No abstract available.

2.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

3.

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.

Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Fuller GN.

Ann Diagn Pathol. 2012 Aug;16(4):255-9. doi: 10.1016/j.anndiagpath.2011.11.003. Epub 2012 Mar 23.

PMID:
22445362
4.

[Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas].

Larsen CJ.

Bull Cancer. 2009 Jun;96(6):641-2. French. No abstract available.

5.

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.

Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ.

Hum Mutat. 2010 Mar;31(3):E1186-99. doi: 10.1002/humu.21201.

PMID:
20077503
6.

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.

Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L.

Int J Biochem Cell Biol. 2016 Apr;73:72-81. doi: 10.1016/j.biocel.2016.02.007. Epub 2016 Feb 6.

PMID:
26860959
7.

Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?

Singh A, Gurav M, Dhanavade S, Shetty O, Epari S.

Neuropathology. 2017 Dec;37(6):582-585. doi: 10.1111/neup.12401. Epub 2017 Aug 7.

PMID:
28782849
8.

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.

Li K, Ouyang L, He M, Luo M, Cai W, Tu Y, Pi R, Liu A.

Oncotarget. 2017 Apr 25;8(17):28865-28879. doi: 10.18632/oncotarget.15868.

9.

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.

Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Goodman JC, Fuller GN.

Ann Diagn Pathol. 2012 Jun;16(3):161-70. doi: 10.1016/j.anndiagpath.2011.08.010. Epub 2011 Dec 24.

PMID:
22197544
10.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5.

PMID:
24590270
11.

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.

Cai J, Zhu P, Zhang C, Li Q, Wang Z, Li G, Wang G, Yang P, Li J, Han B, Jiang C, Sun Y, Jiang T.

Oncotarget. 2016 Mar 29;7(13):16384-95. doi: 10.18632/oncotarget.7650.

12.

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.

Ikota H, Nobusawa S, Arai H, Kato Y, Ishizawa K, Hirose T, Yokoo H.

Brain Tumor Pathol. 2015 Oct;32(4):237-44. doi: 10.1007/s10014-015-0222-8. Epub 2015 May 26.

PMID:
26006098
13.

An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.

Lewandowska MA, Furtak J, Szylberg T, Roszkowski K, Windorbska W, Rytlewska J, Jóźwicki W.

Mol Diagn Ther. 2014 Feb;18(1):45-53. doi: 10.1007/s40291-013-0050-7.

14.

IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?

Labussiere M, Sanson M, Idbaih A, Delattre JY.

Oncologist. 2010;15(2):196-9. doi: 10.1634/theoncologist.2009-0218. Epub 2010 Feb 4. No abstract available.

15.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

16.

Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.

Preusser M, Wöhrer A, Stary S, Höftberger R, Streubel B, Hainfellner JA.

J Neuropathol Exp Neurol. 2011 Aug;70(8):715-23. doi: 10.1097/NEN.0b013e31822713f0.

PMID:
21760534
17.

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.

Sabit H, Nakada M, Furuta T, Watanabe T, Hayashi Y, Sato H, Kato Y, Hamada J.

Brain Tumor Pathol. 2014 Oct;31(4):242-6. doi: 10.1007/s10014-013-0172-y. Epub 2014 Jan 3.

PMID:
24384677
18.

C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.

Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB.

J Neurooncol. 2014 Mar;117(1):53-65. doi: 10.1007/s11060-014-1371-z. Epub 2014 Jan 29.

PMID:
24473683
19.

IDH1 mutation diminishes aggressive phenotype in glioma stem cells.

Yao Q, Cai G, Yu Q, Shen J, Gu Z, Chen J, Shi W, Shi J.

Int J Oncol. 2018 Jan;52(1):270-278. doi: 10.3892/ijo.2017.4186. Epub 2017 Nov 3.

PMID:
29115585
20.

IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.

Neal A, Kwan P, O'Brien TJ, Buckland ME, Gonzales M, Morokoff A.

Epilepsy Behav. 2018 Jan;78:30-36. doi: 10.1016/j.yebeh.2017.10.027. Epub 2017 Dec 22.

PMID:
29172136

Supplemental Content

Support Center